Details of Disease

General Information of Disease (ID: DISX6VF8)

• Disease Name: Diabetic neuropathy
• Disease Class: 8C0Z: Neuropathy
• Definition: A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.
• Disease Hierarchy:
  DIS7KN5G: Peripheral neuropathy
  DISX6VF8: Diabetic neuropathy
• ICD Code: ICD-11: ICD-11: 8C0Z
• Disease Identifiers:
  MONDO ID: MONDO_0006626
  MESH ID: D003929
  UMLS CUI: C0011882
  MedGen ID: 8353
  SNOMED CT ID: 230572002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Capsaicin	DMGMF6V	Approved	Small molecular drug	[1]
Clonidine	DM6RZ9Q	Approved	Small molecular drug	[2]
E-2007	DMJDYNQ	Approved	Small molecular drug	[3]
Epalrestat	DM5OGK0	Approved	Small molecular drug	[4]
Lacosamide	DMVM6QR	Approved	Small molecular drug	[5]
Reboxetine	DM26PRD	Approved	Small molecular drug	[6]

This Disease is Treated as An Indication in 27 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BK-C-0701	DMB52FU	Phase 3	NA	[7]
Donaperminogene seltoplasmid	DMH8IT5	Phase 3	Gene therapy	[8]
GRT-6005	DMHN3PG	Phase 3	Small molecular drug	[9]
Ranirestat	DMD5QRS	Phase 3	Small molecular drug	[10]
BNV-222	DMYFQJL	Phase 2/3	Small molecular drug	[11]
TAK-583	DMILKZ6	Phase 2/3	NA	[12]
ABT-652	DMLEO2Z	Phase 2	NA	[13]
AEG-33773	DMSBLOU	Phase 2	NA	[14]
BMS-954561	DM7XV4R	Phase 2	NA	[15]
CV-301	DMSJZB9	Phase 2	NA	[16]
DA-9801	DMAUWYW	Phase 2	NA	[17]
DCVax-Prostate cancer vaccine	DM72V2C	Phase 2	NA	[18]
Gamunex-C	DM8U7FG	Phase 2	NA	[19]
GRT-3983Y	DMYO8EA	Phase 2	NA	[20]
MEDI7352	DM92SVC	Phase 2	NA	[21]
MK-6096	DM1V78I	Phase 2	Small molecular drug	[22]
NYX-2925	DM1P60V	Phase 2	NA	[23]
PDA-002	DMX60IL	Phase 2	NA	[2]
QR-333	DMKVIWM	Phase 2	NA	[24]
TAK-128	DMHPEFS	Phase 2	NA	[25]
TV1001sr	DMO4UZ6	Phase 2	NA	[2]
AIGIV	DMJVGIH	Phase 1/2	NA	[26]
EXO-230	DM64PM7	Phase 1/2	NA	[27]
T2c-003	DMWIH59	Phase 1/2	NA	[28]
HX-100	DMFRM15	Phase 1	NA	[19]
RTA 901	DMA6JME	Phase 1	Small molecular drug	[29]
RTA-901	DM7C062	Phase 1	NA	[19]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DA-5018	DM48ECA	Discontinued in Phase 2	Small molecular drug	[30]
EAA-090	DMC28Y4	Discontinued in Phase 2	Small molecular drug	[30]
PV-705	DM7NFDR	Discontinued in Phase 2	NA	[31]
TAK-428	DMBUD2Z	Discontinued in Phase 2	NA	[32]
Zenarestat	DMQUSG9	Terminated	Small molecular drug	[34]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMI-004	DMCIQFE	Preclinical	NA	[33]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CIGB-428	DMIMKUT	Investigative	NA	[35]
NG-2	DMJRBZF	Investigative	Small molecular drug	[35]
PF-04577806	DMW0C28	Investigative	NA	[35]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AKR1B1	TTFBNVI	Limited	Biomarker	[37]
HCN2	TT9EUT4	Limited	Biomarker	[38]
PNPLA6	TTWAQU2	Limited	Biomarker	[39]
UCP3	TT12RJK	Limited	Genetic Variation	[40]
CCR8	TTE836A	moderate	Biomarker	[41]
DPYSL2	TTZCW3T	moderate	Biomarker	[42]
NGF	TTDN3LF	moderate	Biomarker	[43]
ATP1A1	TTWK8D0	Strong	Genetic Variation	[44]
BDNF	TTSMLOH	Strong	Biomarker	[45]
CASP3	TTPF2QI	Strong	Biomarker	[46]
CAT	TTPS279	Strong	Genetic Variation	[47]
CHRM2	TTYEG6Q	Strong	Therapeutic	[48]
GRM5	TTHS256	Strong	Biomarker	[49]
HGF	TT4V2JM	Strong	Therapeutic	[50]
IGF1	TTT6LOU	Strong	Biomarker	[51]
INSR	TTCBFJO	Strong	Biomarker	[52]
LEPR	TT0HD6V	Strong	Biomarker	[53]
MME	TT5TKPM	Strong	Biomarker	[54]
MMP2	TTLM12X	Strong	Biomarker	[55]
NGFR	TTEDJN4	Strong	Biomarker	[56]
NTF3	TTZHKV9	Strong	Biomarker	[57]
RNMT	TTG45HY	Strong	Biomarker	[58]
SGK1	TTTV8EJ	Strong	Biomarker	[59]
TKT	TT04R7I	Strong	Genetic Variation	[60]
TLR4	TTISGCA	Strong	Biomarker	[61]
TRPA1	TTELV3W	Strong	Biomarker	[62]
BDKRB1	TTG5QIA	Definitive	Biomarker	[63]
BECN1	TT5M7LN	Definitive	Therapeutic	[64]
CNR1	TT6OEDT	Definitive	Biomarker	[65]
LRRK2	TTK0FEA	Definitive	Biomarker	[66]
MAPK14	TTQBR95	Definitive	Biomarker	[67]
MBP	TT2RY5P	Definitive	Biomarker	[68]
NRG1	TTEH395	Definitive	Therapeutic	[69]
NTRK1	TTTDVOJ	Definitive	Biomarker	[56]
SREBF1	TTER0UB	Definitive	Biomarker	[70]
TGFB1	TTR9XHZ	Definitive	Biomarker	[71]
TGFB2	TTI0KH6	Definitive	Biomarker	[71]
TGFB3	TTWOMY8	Definitive	Biomarker	[71]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC6A6	DTHWCVA	Strong	Biomarker	[72]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
LPO	DEHX1DZ	moderate	Biomarker	[73]
PMM2	DEBRX3L	Strong	Biomarker	[74]

This Disease Is Related to 15 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSL1	OTB06ESI	Limited	Altered Expression	[75]
MFAP4	OT5W64QY	Limited	Biomarker	[76]
NFASC	OTBDUXZT	Limited	Biomarker	[77]
SERPINE2	OTYF5340	Limited	Altered Expression	[78]
COL6A5	OTJT8O80	moderate	Genetic Variation	[79]
SCG2	OTXWUQQL	moderate	Biomarker	[80]
STAP2	OTEB1VVI	moderate	Biomarker	[81]
TMX1	OTX4FHYQ	moderate	Biomarker	[82]
ARIH1	OTO3XDR2	Strong	Biomarker	[83]
DCAF1	OT3ZDVOE	Strong	Biomarker	[84]
MPZ	OTAR2YXH	Strong	Therapeutic	[85]
RPAIN	OTBMXAYK	Strong	Biomarker	[84]
ST3GAL4	OTNENJZQ	Strong	Biomarker	[73]
BAD	OT63ERYM	Definitive	Therapeutic	[69]
HHIP	OT77RQYS	Definitive	Biomarker	[86]

References

• [1] Capsaicin FDA Label
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7050).
• [4] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7472).
• [6] Catecholaminergic and opioidergic system mediated effects of reboxetine on diabetic neuropathic pain. Psychopharmacology (Berl). 2020 Apr;237(4):1131-1145.
• [7] ClinicalTrials.gov (NCT01261143) Randomized, Double-blind Study to Assess the Efficacy and Safety of alpha-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
• [9] Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6.
• [10] ClinicalTrials.gov (NCT00101426) Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT00377598) Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT01207115) A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT00891683) Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT01314222) Diabetic Peripheral Neuropathic Pain (DPNP). U.S. National Institutes of Health.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019475)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033396)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008981)
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] ClinicalTrials.gov (NCT01056315) A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03755934) Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT01021852) Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011). U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT04146896) Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN). U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT00568035) Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [26] ClinicalTrials.gov (NCT00845650) Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV). U.S. National Institutes of Health.
• [27] ClinicalTrials.gov (NCT00544934) Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects. U.S. National Institutes of Health.
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029470)
• [29] ClinicalTrials.gov (NCT02666963) A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults. U.S. National Institutes of Health.
• [30] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016101)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017346)
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020291)
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7418).
• [35] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [36] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [37] The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.Acta Pharmacol Sin. 2019 Jan;40(1):86-97. doi: 10.1038/s41401-018-0043-5. Epub 2018 Jun 21.
• [38] Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy.Sci Transl Med. 2017 Sep 27;9(409):eaam6072. doi: 10.1126/scitranslmed.aam6072.
• [39] Neuropathy target esterase (NTE): overview and future.Chem Biol Interact. 2013 Mar 25;203(1):238-44. doi: 10.1016/j.cbi.2012.10.024. Epub 2012 Dec 3.
• [40] Functional polymorphisms of UCP2 and UCP3 are associated with a reduced prevalence of diabetic neuropathy in patients with type 1 diabetes.Diabetes Care. 2006 Jan;29(1):89-94. doi: 10.2337/diacare.29.01.06.dc05-0757.
• [41] Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target - Evidence from a mouse diabetic neuropathy model.Int Immunopharmacol. 2017 Nov;52:261-271. doi: 10.1016/j.intimp.2017.09.021. Epub 2017 Oct 12.
• [42] Carboxymethylation of CRMP2 is associated with decreased Schwann cell myelination efficiency.Neurosci Res. 2019 Feb;139:58-62. doi: 10.1016/j.neures.2018.08.015. Epub 2018 Sep 5.
• [43] Uncoupling neurotrophic function from nociception of nerve growth factor: what can be learned from a rare human disease?.Neural Regen Res. 2019 Apr;14(4):570-573. doi: 10.4103/1673-5374.247442.
• [44] Genetic and environmental regulation of Na/K adenosine triphosphatase activity in diabetic patients.Metabolism. 2002 Mar;51(3):284-91. doi: 10.1053/meta.2002.29009.
• [45] Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation.Cardiovasc Diabetol. 2017 Feb 8;16(1):20. doi: 10.1186/s12933-017-0505-y.
• [46] Diphenyleneiodonium Mitigates Bupivacaine-Induced Sciatic Nerve Damage in a Diabetic Neuropathy Rat Model by Attenuating Oxidative Stress.Anesth Analg. 2017 Aug;125(2):653-661. doi: 10.1213/ANE.0000000000002186.
• [47] Genetics of diabetic neuropathy: Systematic review, meta-analysis and trial sequential analysis.Ann Clin Transl Neurol. 2019 Oct;6(10):1996-2013. doi: 10.1002/acn3.50892. Epub 2019 Sep 26.
• [48] The M2-muscarinic receptor inhibits the development of streptozotocin-induced neuropathy in mouse urinary bladder.J Pharmacol Exp Ther. 2010 Oct;335(1):239-48. doi: 10.1124/jpet.110.169995. Epub 2010 Jul 12.
• [49] Regulation of increased glutamatergic input to spinal dorsal horn neurons by mGluR5 in diabetic neuropathic pain.J Neurochem. 2010 Jan;112(1):162-72. doi: 10.1111/j.1471-4159.2009.06437.x. Epub 2009 Oct 15.
• [50] Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.Ann Clin Transl Neurol. 2015 May;2(5):465-78. doi: 10.1002/acn3.186. Epub 2015 Mar 5.
• [51] Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.Neurobiol Dis. 2017 Jan;97(Pt B):103-113. doi: 10.1016/j.nbd.2016.04.007. Epub 2016 Apr 30.
• [52] Disrupting insulin signaling in Schwann cells impairs myelination and induces a sensory neuropathy.Glia. 2020 May;68(5):963-978. doi: 10.1002/glia.23755. Epub 2019 Nov 23.
• [53] Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy.J Pharmacol Exp Ther. 2014 Feb;348(2):281-92. doi: 10.1124/jpet.113.210435. Epub 2013 Nov 21.
• [54] The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy.Exp Diabetes Res. 2009;2009:431980. doi: 10.1155/2009/431980. Epub 2010 Feb 3.
• [55] Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy.Neurol Sci. 2010 Dec;31(6):705-16. doi: 10.1007/s10072-010-0243-3. Epub 2010 Mar 6.
• [56] Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy.Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):473-83. doi: 10.1002/dmrr.326.
• [57] Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength.Brain. 2009 Oct;132(Pt 10):2724-33. doi: 10.1093/brain/awp208. Epub 2009 Aug 20.
• [58] Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies.J Neurol Sci. 2010 Mar 15;290(1-2):115-22. doi: 10.1016/j.jns.2009.10.006. Epub 2009 Nov 17.
• [59] Expression of serum and glucocorticoid-inducible kinase1 in diabetic rats and its modulation by fluvastatin.J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):651-4. doi: 10.1007/BF02896161.
• [60] Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes.Diabetes Metab Res Rev. 2017 May;33(4). doi: 10.1002/dmrr.2811. Epub 2016 May 15.
• [61] Streptozotocin-induced diabetic hyperalgesia in rats is associated with upregulation of Toll-like receptor 4 expression.Neurosci Lett. 2012 Sep 20;526(1):54-8. doi: 10.1016/j.neulet.2012.08.012. Epub 2012 Aug 15.
• [62] Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation.Pain. 2019 Nov;160(11):2497-2507. doi: 10.1097/j.pain.0000000000001644.
• [63] Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy.J Neuroinflammation. 2010 Jun 29;7(1):36. doi: 10.1186/1742-2094-7-36.
• [64] Jinmaitong alleviates the diabetic peripheral neuropathy by inducing autophagy.Chin J Integr Med. 2016 Mar;22(3):185-92. doi: 10.1007/s11655-015-2164-8. Epub 2015 Mar 31.
• [65] Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.Pharmacology. 2008;82(3):193-200. doi: 10.1159/000156485. Epub 2008 Sep 23.
• [66] Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model.Cell Death Dis. 2014 May 8;5(5):e1217. doi: 10.1038/cddis.2014.184.
• [67] Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy.J Neurosci. 2008 Jun 25;28(26):6652-8. doi: 10.1523/JNEUROSCI.5530-07.2008.
• [68] Beneficial effect of TNF- inhibition on diabetic peripheral neuropathy.J Neuroinflammation. 2013 Jun 4;10:69. doi: 10.1186/1742-2094-10-69.
• [69] Traditional chinese medicine tang-luo-ning ameliorates sciatic nerve injuries in streptozotocin-induced diabetic rats.Evid Based Complement Alternat Med. 2013;2013:989670. doi: 10.1155/2013/989670. Epub 2013 Oct 28.
• [70] Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice.Circ Res. 2009 Jul 31;105(3):287-94. doi: 10.1161/CIRCRESAHA.109.193995. Epub 2009 May 7.
• [71] Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy.Exp Neurol. 2008 Jun;211(2):469-79. doi: 10.1016/j.expneurol.2008.02.011. Epub 2008 Mar 2.
• [72] Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy.Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E620-8. doi: 10.1152/ajpendo.00287.2009. Epub 2009 Jul 14.
• [73] Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis.Life Sci. 2019 Jan 1;216:101-110. doi: 10.1016/j.lfs.2018.10.055. Epub 2018 Oct 28.
• [74] Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.Dis Model Mech. 2019 Nov 11;12(11):dmm040584. doi: 10.1242/dmm.040584.
• [75] Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.Antioxid Redox Signal. 2014 Aug 1;21(4):588-600. doi: 10.1089/ars.2013.5248. Epub 2013 Oct 5.
• [76] Association between microfibrillar-associated protein 4 (MFAP4) and micro- and macrovascular complications in long-term type 1 diabetes mellitus.Acta Diabetol. 2017 Apr;54(4):367-372. doi: 10.1007/s00592-016-0953-y. Epub 2016 Dec 30.
• [77] Nodes of Ranvier in skin biopsies of patients with diabetes mellitus.J Peripher Nerv Syst. 2017 Sep;22(3):182-190. doi: 10.1111/jns.12224. Epub 2017 Jun 23.
• [78] miR?99a?p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2.Mol Med Rep. 2017 Sep;16(3):2417-2424. doi: 10.3892/mmr.2017.6874. Epub 2017 Jun 28.
• [79] COL6A5 variants in familial neuropathic chronic itch.Brain. 2017 Mar 1;140(3):555-567. doi: 10.1093/brain/aww343.
• [80] Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy.FASEB J. 2018 Sep;32(9):4815-4823. doi: 10.1096/fj.201701391R. Epub 2018 Apr 13.
• [81] Characterization of diabetic neuropathy progression in a mouse model of type 2 diabetes mellitus.Biol Open. 2018 Sep 5;7(9):bio036830. doi: 10.1242/bio.036830.
• [82] Characterization of Nave and Vitamin C-Treated Mouse Schwann Cell Line MSC80: Induction of the Antioxidative Thioredoxin Related Transmembrane Protein 1.J Proteome Res. 2018 Sep 7;17(9):2925-2936. doi: 10.1021/acs.jproteome.8b00022. Epub 2018 Aug 10.
• [83] Aldose reductase structures: implications for mechanism and inhibition.Cell Mol Life Sci. 2004 Apr;61(7-8):750-62. doi: 10.1007/s00018-003-3403-2.
• [84] Diabetic neuropathy: electrophysiological and morphological study of peripheral nerve degeneration and regeneration in transgenic mice that express IFNbeta in beta cells.Muscle Nerve. 2010 May;41(5):630-41. doi: 10.1002/mus.21564.
• [85] Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation.J Lipid Res. 2012 Feb;53(2):300-10. doi: 10.1194/jlr.M021188. Epub 2011 Dec 7.
• [86] The role of hedgehog-interacting protein in maintaining cavernous nerve integrity and adult penile morphology.J Sex Med. 2009 Sep;6(9):2480-93. doi: 10.1111/j.1743-6109.2009.01349.x. Epub 2009 Jun 9.